Not having developed a symptomatic form of COVID-19 within the last 3 months before inclusion
Eligible to the vaccination against SARS-CoV-2
Affiliation to French social security or receiving such a regime,
Signed informed consent
Ability to comply with the study protocol, in the Investigator's judgment
Cancer patients
Patients under active anticancer treatment: in adjuvant or neoadjuvant setting or in first line of treatment in metastatic setting. Except for prostate cancer (until metastatic castration-resistant prostate cancer); and breast cancer hormonal receptor positive/HER2 negative (until apparition of hormonal resistance).
Patients in follow-up (active treatment \< 3 months).
Elderly:
Age ≥ 70 years old
Healthy person:
Age ≥ 18 years old and \< 70 years old
You may not be if
Patient under guardianship, guardianship or under the protection of justice
Receipt of a live, attenuated vaccine within 4 weeks prior to the initiation of treatment or anticipation that such a live, attenuated vaccine will be required during the study.
Clareo Health | COVID-19-Study of Immune Responses Following Vaccination Against SARS-CoV-2
